AI주식인사이트AI Stock Insight
C

박셀바이오

323990KOSDAQ자연과학 및 공학 연구개발업

53.5 / 100

Reference Date: 2026-04-13

Financial Score21.0 / 40
News Sentiment17.5 / 25
Momentum5.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Declined 6.1% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Parkcell Bio is a biotech company specializing in cancer immunotherapy, developing various platforms such as Vax-NK and Vax-CAR for immune cell therapies and targeted anticancer drugs. It also expands its pet healthcare business through its veterinary immunomodulatory drug 'Vaxleukin-15' and has enhanced its commercialization capabilities by constructing an advanced manufacturing platform following the completion of its new headquarters in 2025.

Number of Employees

91people

Average Salary

49.3M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 120.074.0Point
PBR
2.98Industry Average 3.824.0Point

In line with industry avg

ROE
-20.04Industry Average -32.113.5Point

Below industry avg

Debt Ratio
3.69Industry Average 7.526.5Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲7004.4% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼16.9% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -17.7% (declining, 3yr)

Detailed News Sentiment

1 totalPositive 0Neutral 1Negative 0Average Sentiment Score 70

Detailed Momentum

52-week position1.0Point

Near 52w low (6%, downtrend)

Current 7,840Won52-week high 11,00052-week low 7,630
1-month return2.0Point

1m -6.11% (slight drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-27
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-27
  • Neutral정기주주총회결과2026-03-24
  • Neutral감사보고서제출2026-03-16
  • Neutral사업보고서 (2025.12)2026-03-16